Francis et al. (2014) demonstrated that multiple EGFR mutational variants exist within glioblastoma tumors, includingEGFRvII and EGFR carboxyl-terminal deletions in the bulk tumor, highlighting the molecular heterogeneity of EGFR alterations in GBM. This evidence concerns the gene EGFR and neoplasm.